Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321), a biopharmaceutical company based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a Phase II clinical study for its Category 1 innovative drug, chiauranib. The drug will be evaluated in combination with chemotherapy as a first-line treatment for advanced pancreatic cancer.
Chipscreen’s chiauranib is a highly selective small-molecule inhibitor of Aurora B, CSFR1, VEGFR/PDGR, and c-Kit, offering a dual mechanism of action by inhibiting both angiogenesis and cell mitosis in cancer cells, as well as regulating the tumor microenvironment. The drug targets tumors with abnormal gene activity related to DNA replication and telomere maintenance by inhibiting the cell cycle regulatory kinase Aurora B or by combining with other cell cycle suppressive chemotherapy drugs that target DNA replication, topoisomerase, and microtubule proteins, creating synthetic lethality that inhibits tumor cell proliferation. By inhibiting VEGFR and PDGFR, which are related to angiogenesis, chiauranib can prevent tumor neovascularization, reducing the blood supply and growth of tumors. Additionally, by inhibiting CSF1R and DDR, which are related to immune cell proliferation and activation, chiauranib can suppress local immunosuppressive cells within tumors and enhance the body’s immune surveillance and clearance functions against cancer cells.- Flcube.com
